Matches in Nanopublications for { ?s ?p "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_assertion description "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP545364.RAD2JgYBc8xk-O-3xtkyu6m_xq6UF5kGCEcIwluIXBKZY130_provenance.
- NP634061.RAP-0u0kJYuElgDXhjJu286miKaf9Ms6MzJmgRXS83Dus130_assertion description "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP634061.RAP-0u0kJYuElgDXhjJu286miKaf9Ms6MzJmgRXS83Dus130_provenance.
- assertion description "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP378712.RAbgDZzH2SJfruTduGV-T2CS6bhyJ-VSZoKzLx_EpqrOQ130_assertion description "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP378712.RAbgDZzH2SJfruTduGV-T2CS6bhyJ-VSZoKzLx_EpqrOQ130_provenance.
- NP378711.RAJEH44CWTByFaJXRyuVd9iezvse1zqjJm6y7RqM38TtU130_assertion description "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP378711.RAJEH44CWTByFaJXRyuVd9iezvse1zqjJm6y7RqM38TtU130_provenance.
- NP378709.RAzWUVOdvJ5l0KlsiSXV2RCVKDkq7OQMfShTGNUd8cPtk130_assertion description "[The first human trial in cardiovascular disease started in 1994 treating peripheral vascular disease with vascular endothelial growth factor (VEGF) and since then, many different potent angiogenic growth factors have been tested in clinical trials for the treatment of peripheral arterial disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP378709.RAzWUVOdvJ5l0KlsiSXV2RCVKDkq7OQMfShTGNUd8cPtk130_provenance.